Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

10.17
+0.30003.04%
Post-market: 10.04-0.1300-1.28%19:30 EDT
Volume:2.08M
Turnover:21.39M
Market Cap:867.64M
PE:-5.83
High:10.75
Open:9.84
Low:9.68
Close:9.87
52wk High:25.77
52wk Low:7.24
Shares:85.31M
Float Shares:54.48M
Volume Ratio:1.18
T/O Rate:3.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:1.78
PE(LYR):-21.87

Loading ...

Monte Rosa Therapeutics, - Eligible for Tiered Royalties on Ex-U.S. Net Sales of Mrt-6160

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Novartis to Fund Phase 2; Monte Rosa to Co-Fund Phase 3 and Share 30% U.S. Profits/Losses

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Eligible for up to $2.10 Bln in Milestones Starting with Phase 2 Initiation

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - to Receive $50 Mln Milestone Payment from Novartis for First Patient Visit

THOMSON REUTERS
·
Sep 08

Monte Rosa Grants Inducement Awards to New Hires, Including Options Priced at $14.31

Reuters
·
Sep 03

Monte Rosa Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 03

Monte Rosa Therapeutics to Present at Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Sep 01

Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive

Simply Wall St.
·
Aug 26

Monte Rosa Therapeutics Price Target Maintained with a $28.00/Share by Guggenheim

Dow Jones
·
Aug 25

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Aug 25

Monte Rosa Doses First Patient in Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in mCRPC

Reuters
·
Aug 24

Monte Rosa Therapeutics Announces First Patient Dosed in Modefire-1, a Phase 2 Study of Mrt-2359 in Combination with Apalutamide in Patients with Ar Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
Aug 24

Monte Rosa Therapeutics - to Provide Phase 1/2 Study Update on Mrt-2359 Plus Enzalutamide by Year-End

THOMSON REUTERS
·
Aug 24

Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)

Simply Wall St.
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)

TIPRANKS
·
Aug 13

Monte Rosa Therapeutics is Maintained at Overweight by Wells Fargo

Dow Jones
·
Aug 07

Gyre Therapeutics Q2 Revenue Beats Estimates on Higher Etuary Sales Volumes

Reuters
·
Aug 07

Relay Therapeutics Q2 Revenue Misses Estimates on Higher R&D Expenses; Net Loss Widens

Reuters
·
Aug 07

Monte Rosa Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate

Benzinga Earnings
·
Aug 06